Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis

ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for th...

Full description

Saved in:
Bibliographic Details
Published in:Neurology and clinical neuroscience 2021-01, Vol.9 (1), p.114-117
Main Authors: García‐Grimshaw, Miguel, Jiménez‐Ruiz, Amado, Vega‐Boada, Felipe Arturo, Falcón‐Antonio, Orlando Emmanuel, Barrera‐Vargas, Ana, Valdés‐Ferrer, Sergio Iván
Format: Article
Language:English
Subjects:
Case reports
Central nervous system
Lupus
Lupus nephritis
Lymphoma
Mycophenolate mofetil
Mycophenolic acid
Nephritis
Nervous system
Non-Hodgkin's lymphoma
non‐Hodgkin lymphoma
primary central nervous system lymphoma
Systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3
cites cdi_FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3
container_end_page 117
container_issue 1
container_start_page 114
container_title Neurology and clinical neuroscience
container_volume 9
creator García‐Grimshaw, Miguel
Jiménez‐Ruiz, Amado
Vega‐Boada, Felipe Arturo
Falcón‐Antonio, Orlando Emmanuel
Barrera‐Vargas, Ana
Valdés‐Ferrer, Sergio Iván
description ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for the induction and maintenance of lupus nephritis. The evidence regarding the development of PCNSL in patients with systemic lupus erythematosus (SLE) treated with MMF is limited to a few case reports. We present the case of a 40‐year‐old woman with a history of SLE who developed PCNSL while treated with MMF for lupus nephritis and a review of all published cases with this association.
doi_str_mv 10.1111/ncn3.12457
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2484177531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2484177531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouKx78RcEvAm7Nm3SJEdZ_IJFPeg5pGlKs7ZJTVKX_nuz1oMn38sMwzMz8ABwibINSrmxyhYblGNCT8AizzBfY0SL0z_9OViFsM9SOC8QZwvw8epNL_0ElbbRyw5a7b_cGGCYQtQ97KZ-aF0vobFQwkFGkzgYvZZR1_BgYgv7Sbmh1dZ1aQZ71-hoOtg4D7txSJesHlpvogkX4KyRXdCr37oE7_d3b9vH9e7l4Wl7u1urnDG65rrChDdFlWuGEKYKUck5KmnDESsZoRXJSY4anDVEq5KXtcS8zipVlxQzUhVLcDXfHbz7HHWIYu9Gb9NLkWOWPFBSoERdz5TyLgSvGzHMKgTKxNGnOPoUPz4TjGb4YDo9_UOK5-1zMe98AycmeIs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2484177531</pqid></control><display><type>article</type><title>Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis</title><source>Wiley</source><creator>García‐Grimshaw, Miguel ; Jiménez‐Ruiz, Amado ; Vega‐Boada, Felipe Arturo ; Falcón‐Antonio, Orlando Emmanuel ; Barrera‐Vargas, Ana ; Valdés‐Ferrer, Sergio Iván</creator><creatorcontrib>García‐Grimshaw, Miguel ; Jiménez‐Ruiz, Amado ; Vega‐Boada, Felipe Arturo ; Falcón‐Antonio, Orlando Emmanuel ; Barrera‐Vargas, Ana ; Valdés‐Ferrer, Sergio Iván</creatorcontrib><description>ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for the induction and maintenance of lupus nephritis. The evidence regarding the development of PCNSL in patients with systemic lupus erythematosus (SLE) treated with MMF is limited to a few case reports. We present the case of a 40‐year‐old woman with a history of SLE who developed PCNSL while treated with MMF for lupus nephritis and a review of all published cases with this association.</description><identifier>ISSN: 2049-4173</identifier><identifier>EISSN: 2049-4173</identifier><identifier>DOI: 10.1111/ncn3.12457</identifier><language>eng</language><publisher>Tokyo: Wiley Subscription Services, Inc</publisher><subject>Case reports ; Central nervous system ; Lupus ; Lupus nephritis ; Lymphoma ; Mycophenolate mofetil ; Mycophenolic acid ; Nephritis ; Nervous system ; Non-Hodgkin's lymphoma ; non‐Hodgkin lymphoma ; primary central nervous system lymphoma ; Systemic lupus erythematosus</subject><ispartof>Neurology and clinical neuroscience, 2021-01, Vol.9 (1), p.114-117</ispartof><rights>2020 Societas Neurologica Japonica (Japanese Society of Neurology) and John Wiley &amp; Sons Australia, Ltd</rights><rights>2021 Japanese Society of Neurology and John Wiley &amp; Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3</citedby><cites>FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3</cites><orcidid>0000-0002-0257-3107 ; 0000-0001-5287-1068 ; 0000-0002-4863-6484 ; 0000-0002-1754-0500 ; 0000-0003-3466-924X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>García‐Grimshaw, Miguel</creatorcontrib><creatorcontrib>Jiménez‐Ruiz, Amado</creatorcontrib><creatorcontrib>Vega‐Boada, Felipe Arturo</creatorcontrib><creatorcontrib>Falcón‐Antonio, Orlando Emmanuel</creatorcontrib><creatorcontrib>Barrera‐Vargas, Ana</creatorcontrib><creatorcontrib>Valdés‐Ferrer, Sergio Iván</creatorcontrib><title>Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis</title><title>Neurology and clinical neuroscience</title><description>ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for the induction and maintenance of lupus nephritis. The evidence regarding the development of PCNSL in patients with systemic lupus erythematosus (SLE) treated with MMF is limited to a few case reports. We present the case of a 40‐year‐old woman with a history of SLE who developed PCNSL while treated with MMF for lupus nephritis and a review of all published cases with this association.</description><subject>Case reports</subject><subject>Central nervous system</subject><subject>Lupus</subject><subject>Lupus nephritis</subject><subject>Lymphoma</subject><subject>Mycophenolate mofetil</subject><subject>Mycophenolic acid</subject><subject>Nephritis</subject><subject>Nervous system</subject><subject>Non-Hodgkin's lymphoma</subject><subject>non‐Hodgkin lymphoma</subject><subject>primary central nervous system lymphoma</subject><subject>Systemic lupus erythematosus</subject><issn>2049-4173</issn><issn>2049-4173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMouKx78RcEvAm7Nm3SJEdZ_IJFPeg5pGlKs7ZJTVKX_nuz1oMn38sMwzMz8ABwibINSrmxyhYblGNCT8AizzBfY0SL0z_9OViFsM9SOC8QZwvw8epNL_0ElbbRyw5a7b_cGGCYQtQ97KZ-aF0vobFQwkFGkzgYvZZR1_BgYgv7Sbmh1dZ1aQZ71-hoOtg4D7txSJesHlpvogkX4KyRXdCr37oE7_d3b9vH9e7l4Wl7u1urnDG65rrChDdFlWuGEKYKUck5KmnDESsZoRXJSY4anDVEq5KXtcS8zipVlxQzUhVLcDXfHbz7HHWIYu9Gb9NLkWOWPFBSoERdz5TyLgSvGzHMKgTKxNGnOPoUPz4TjGb4YDo9_UOK5-1zMe98AycmeIs</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>García‐Grimshaw, Miguel</creator><creator>Jiménez‐Ruiz, Amado</creator><creator>Vega‐Boada, Felipe Arturo</creator><creator>Falcón‐Antonio, Orlando Emmanuel</creator><creator>Barrera‐Vargas, Ana</creator><creator>Valdés‐Ferrer, Sergio Iván</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-0257-3107</orcidid><orcidid>https://orcid.org/0000-0001-5287-1068</orcidid><orcidid>https://orcid.org/0000-0002-4863-6484</orcidid><orcidid>https://orcid.org/0000-0002-1754-0500</orcidid><orcidid>https://orcid.org/0000-0003-3466-924X</orcidid></search><sort><creationdate>202101</creationdate><title>Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis</title><author>García‐Grimshaw, Miguel ; Jiménez‐Ruiz, Amado ; Vega‐Boada, Felipe Arturo ; Falcón‐Antonio, Orlando Emmanuel ; Barrera‐Vargas, Ana ; Valdés‐Ferrer, Sergio Iván</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Case reports</topic><topic>Central nervous system</topic><topic>Lupus</topic><topic>Lupus nephritis</topic><topic>Lymphoma</topic><topic>Mycophenolate mofetil</topic><topic>Mycophenolic acid</topic><topic>Nephritis</topic><topic>Nervous system</topic><topic>Non-Hodgkin's lymphoma</topic><topic>non‐Hodgkin lymphoma</topic><topic>primary central nervous system lymphoma</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García‐Grimshaw, Miguel</creatorcontrib><creatorcontrib>Jiménez‐Ruiz, Amado</creatorcontrib><creatorcontrib>Vega‐Boada, Felipe Arturo</creatorcontrib><creatorcontrib>Falcón‐Antonio, Orlando Emmanuel</creatorcontrib><creatorcontrib>Barrera‐Vargas, Ana</creatorcontrib><creatorcontrib>Valdés‐Ferrer, Sergio Iván</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Neurology and clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García‐Grimshaw, Miguel</au><au>Jiménez‐Ruiz, Amado</au><au>Vega‐Boada, Felipe Arturo</au><au>Falcón‐Antonio, Orlando Emmanuel</au><au>Barrera‐Vargas, Ana</au><au>Valdés‐Ferrer, Sergio Iván</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis</atitle><jtitle>Neurology and clinical neuroscience</jtitle><date>2021-01</date><risdate>2021</risdate><volume>9</volume><issue>1</issue><spage>114</spage><epage>117</epage><pages>114-117</pages><issn>2049-4173</issn><eissn>2049-4173</eissn><abstract>ABSTRACT Primary central nervous system lymphoma is a rare and aggressive form of extranodal non‐Hodgkin lymphoma, and its occurrence in pharmacologically immunosuppressed patients has increased over the years. Currently, mycophenolate mofetil (MMF) is one of the recommended treatment options for the induction and maintenance of lupus nephritis. The evidence regarding the development of PCNSL in patients with systemic lupus erythematosus (SLE) treated with MMF is limited to a few case reports. We present the case of a 40‐year‐old woman with a history of SLE who developed PCNSL while treated with MMF for lupus nephritis and a review of all published cases with this association.</abstract><cop>Tokyo</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/ncn3.12457</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0257-3107</orcidid><orcidid>https://orcid.org/0000-0001-5287-1068</orcidid><orcidid>https://orcid.org/0000-0002-4863-6484</orcidid><orcidid>https://orcid.org/0000-0002-1754-0500</orcidid><orcidid>https://orcid.org/0000-0003-3466-924X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2049-4173
ispartof Neurology and clinical neuroscience, 2021-01, Vol.9 (1), p.114-117
issn 2049-4173
2049-4173
language eng
recordid cdi_proquest_journals_2484177531
source Wiley
subjects Case reports
Central nervous system
Lupus
Lupus nephritis
Lymphoma
Mycophenolate mofetil
Mycophenolic acid
Nephritis
Nervous system
Non-Hodgkin's lymphoma
non‐Hodgkin lymphoma
primary central nervous system lymphoma
Systemic lupus erythematosus
title Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T02%3A05%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20central%20nervous%20system%20lymphoma%20in%20a%20patient%20treated%20with%20mycophenolate%20mofetil%20for%20lupus%20nephritis&rft.jtitle=Neurology%20and%20clinical%20neuroscience&rft.au=Garc%C3%ADa%E2%80%90Grimshaw,%20Miguel&rft.date=2021-01&rft.volume=9&rft.issue=1&rft.spage=114&rft.epage=117&rft.pages=114-117&rft.issn=2049-4173&rft.eissn=2049-4173&rft_id=info:doi/10.1111/ncn3.12457&rft_dat=%3Cproquest_cross%3E2484177531%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2887-9eb459f3b2e81147c17a99167f9186857b52521f40f5ec696da49d0bcd67485b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2484177531&rft_id=info:pmid/&rfr_iscdi=true